{"filings":[{"id":3413396,"accession_number":"0001213900-26-108780","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-10-13T13:10:12+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apimeds unit MindWave signs 2-year deal with BlockAssure to build AssureChain insurance network","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals US (NYSE American: APUS), signed a 2-year master service agreement with BlockAssure Inc. on Oct. 4, 2026.","MindWave will build, deploy and operate AssureChain, a dedicated subnet of MindChain running BlockAssure's insurance contracts, policies, reinsurance treaties and claims on-chain.","Consideration: fixed development fee paid in quarterly installments, later O&M fees to be agreed, plus 20% of AssureCoin's total supply, fully vested on delivery, with 2-year anti-dilution.","Development is planned over four quarters against milestones; BlockAssure acceptance-tests each module, then MindWave handles hosting, validator operations, maintenance and helpdesk support.","Agreement took effect Oct. 4, 2026, auto-renews for one-year periods unless either party gives 90 days' notice; MindWave is BlockAssure's exclusive blockchain provider during the term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3191357,"accession_number":"0001213900-26-105484","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-10-01T13:15:15+00:00","items":["5.02","9.01"],"status":"ready","headline":"Apimeds names Eric Sherb CFO effective Oct 1; Interim CFO Erick Frim resigned Sept 29","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erick Frim resigned as Interim CFO effective September 29, 2026; the company said the resignation was not due to any disagreement on operations, policies or practices.","The Board appointed Eric Sherb, age 40, as CFO effective October 1, 2026, serving as principal financial officer and principal accounting officer.","Sherb is a CPA with over 18 years of capital markets experience and founded EMS Consulting Services, LLC in January 2019, where he remains Principal.","Employment Agreement provides a base salary of $60,000 per year; no equity awards granted at signing, and no Item 404(a) transactions or family ties to the Board or executives.","Sherb has been fractional CFO of MindWave Innovations Inc., a wholly owned subsidiary, since February 2026; that engagement terminates with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3153556,"accession_number":"0001213900-26-104668","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-09-29T20:15:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apimeds unit MindWave signs 12-month blockchain infrastructure deals with AQUAE and Flash Sports & Media","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MindWave, a wholly owned Apimeds (NYSE American: APUS) subsidiary, will deploy its MindChain infrastructure to power AQUAEChain under a 12-month agreement with AQUAE Holdings.","AQUAE deal includes software development and service fees plus an allocation equal to 20% of total ALCI Credits issued and outstanding, calculated quarterly using the MindChain ledger.","MindWave also signed a 12-month agreement with Flash Sports & Media Holdings (FLZH) to build and operate FlashChain on a dedicated MindChain Layer-2 subnet.","FLZH consideration includes FLZH common shares and 20% of total FLASH TOKEN supply, plus an annual maintenance fee equal to 50% of applicable contract consideration; dollar value undisclosed.","Agreements cover T20 cricket broadcast support, digital ticket authentication and smart contracts; AQUAE deal effective Sept. 14, 2026, with possible five-year extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3026601,"accession_number":"0001213900-26-102321","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-09-23T00:18:52+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Apimeds completes 1-for-10 reverse stock split; share count falls to 1.51M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective 12:01 a.m. ET on July 24, 2026; every 10 shares combined into 1 share.","Shares outstanding reduced from 15,091,180 to 1,509,118; 33,506 additional shares issued for fractional rounding.","Par value reduced from $0.01 to $0.001 per share; authorized shares unchanged at 100M common, 10M preferred.","Common stock trades on NYSE American under 'APUS' on split-adjusted basis; new CUSIP 03771D201.","Proportionate adjustments made to outstanding equity awards and warrants and their exercise prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2806996,"accession_number":"0001213900-26-099002","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-09-11T13:10:36+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Apimeds amends settlement to restructure board; appoints Chae director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On Sep 10, 2026, company amended settlement with Inscobee Parties, altering Board structure.","Interim Board set to only Kogan, O'Donnell, Weintraub, and Chae; no removals without Menon/Inscobee consent.","Post-conversion Board: 4 MindWave-nominated independents, 2 Menon nominees (incl. Menon), and Chae.","Sungjoon Chae appointed to Board effective Sep 10, 2026; already Co-CEO since May 2026.","Agreement is Delaware-governed; full text filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2411916,"accession_number":"0001213900-26-092680","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-08-21T21:12:40+00:00","items":["1.01","9.01"],"status":"ready","headline":"Apimeds acquires Apitox rights from FreeT: Korean clinic market, 25% US royalty","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On Aug 19, 2026, Apimeds entered an Assignment Agreement with FreeT Inc. (successor to CNP Roen/Inscobee).","Assigned rights include 100% of Apitox Korean medicine-clinic market rights and 25% royalty on US Apitox economic proceeds.","Also granted 25% revenue participation on net proceeds from overseas rights deals plus quarterly clinical and commercialization updates.","Company assumes no pre-effective-date liabilities; rights exclude global rights not held by FreeT and underlying Apitox IP.","FreeT will support continued development and expansion and pursue future grants of non-US Apitox territories to Apimeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2108396,"accession_number":"0001213900-26-086244","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-08-06T21:25:33+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apimeds appoints Dr. Christopher Kim as Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Christopher Kim appointed Chief Scientific Officer effective August 5, 2026.","He will lead scientific, clinical, and regulatory development of the APITOX program.","Dr. Kim has extensive expertise in APITOX research, development, and clinical advancement.","Appointment provides continuity and strengthens long-term development strategy toward commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1610798,"accession_number":"0001213900-26-077591","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-07-13T20:30:43+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apimeds Pharmaceuticals announces 1-for-10 reverse stock split effective July 24, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio, effective 12:01 a.m. ET on July 24, 2026.","Stock will trade on NYSE American under symbol APUS on split-adjusted basis from July 24.","New CUSIP number for post-split common stock is 03771D201.","Previously expected effective date of March 26, 2026, was delayed; now set for July 24, 2026.","Every ten pre-split shares will combine into one post-split share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96605,"accession_number":"0001213900-26-052036","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.","No family relationships or related party transactions with company officers or directors.","Compensation terms for Chae have not yet been determined; will be disclosed when finalized.","Chae holds a Master of Architecture in Urban Design from Harvard University and specializes in large-scale real estate and urban regeneration.","Existing CEO Dr. Vin Menon continues as CEO; Chae serves as Co-CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96604,"accession_number":"0001213900-26-051125","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Apimeds settles merger dispute; Lokahi provides $4M working capital; board to transition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves all disputes from Dec 2025 Merger Agreement; Lokahi retains Apitox program assets valued at ~$2.2M.","Lokahi provides $4M working capital to Company and forgives $750k advance; 51% of Lokahi stock to be distributed to Emerson.","Newco formed as wholly owned subsidiary, to be spun off within 12 months; 10% of net financing proceeds allocated to Newco.","Board changes: Stockholder Consents voided; Koo to resign; interim board of three; then three new independent directors appointed by Inscobee.","Forbearance Agreement with Alto Opportunity Master Fund extends forbearance on $11M note defaults through June 30, 2026, subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96603,"accession_number":"0001213900-26-046671","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.","Has initial 6-month cure period until October 15, 2026; expects to file 10-K by April 30.","Common stock trades with '.LF' designation; trading halt from April 2 remains in effect.","If not cured, NYSE may grant up to 6 additional months or commence delisting procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96602,"accession_number":"0001213900-26-044657","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apimeds expects NYSE notice for late 10-K filing; targets April 30","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed Form 12b-25 on March 31, 2026 for FY 2025 10-K; will not file within 15-day extension.","Expects NYSE American non-compliance notice due to failure to timely file 10-K.","Plans to file 10-K by April 30, 2026; no assurance given.","Delay driven by ongoing preparation of financial statements and audit completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96601,"accession_number":"0001213900-26-042017","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K/A","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Apimeds: Majority stockholder consent to remove directors/officers is null and void","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inscobee Inc. and Apimeds, Inc. attempted written consent to remove directors Kogan, Koo, O’Donnell, Weintraub and officers Menon (CEO) and Frim (CFO).","Company determined consent invalid due to violations of irrevocable proxy, consent waiver, and anti-frustration covenant in Support Agreement.","Support Agreement expressly states any action taken in violation is null and void; consent void ab initio.","Company will proceed with actions described in Schedule 14C Information Statement filed Feb 27, 2026, mailed March 5, 2026.","This Amendment No. 1 clarifies the previously reported actions are of no force or effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110642,"accession_number":"0001213900-26-034786","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Apimeds faces hostile takeover attempt by Inscobee; company says consent void, files emergency action","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.","Company states the consent violates the irrevocable proxy granted under the Support Agreement from Dec 1, 2025.","Inscobee used 6,416,365 shares subject to proxy; without those, consent lacks majority under Delaware law.","Company will file emergency action in Delaware Court of Chancery under 8 Del. C. § 225 to void consent.","Purported new board approved business expansions without authorization; company disputes them."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110641,"accession_number":"0001213900-26-033832","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["5.02","8.01","5.03","9.01"],"status":"ready","headline":"Apimeds US board and CEO ousted; new board approves expansion into Korean cosmetics and photo booth","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Majority stockholders removed directors Elona Kogan, Jakap Koo, Carol O’Donnell, Dr. Bennett Weintraub via written consent.","CEO Vin Menon and CFO Erick Frim removed; Youngjik Cho appointed CEO, Junyoung Yu as Secretary.","New board approved non-binding MOUs with Assemble, Hilluck (cosmetics distribution) and LK Ventures (Life4Cuts photo booth platform).","Company delays previously announced 1-for-10 reverse stock split; board will continue to evaluate timing.","MindWave issued unauthorized press release challenging the consent; company intends to vigorously defend validity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110640,"accession_number":"0001213900-26-028332","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apimeds Pharmaceuticals to effect 1-for-10 reverse stock split on March 26, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 1-for-10 reverse stock split via written consent in December 2025.","Reverse split effective 12:01 a.m. ET March 26, 2026; trading begins on split-adjusted basis same day.","Every 10 pre-split shares convert to 1 share; new CUSIP 03771D201.","Company expects to file charter amendment with Delaware Secretary of State around March 25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110638,"accession_number":"0001213900-26-017323","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K/A","filed_at":"2026-02-17T23:59:59+00:00","items":["9.01","2.01"],"status":"ready","headline":"MindWave posts six-month net loss $6.6M on zero revenue; digital assets $132.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $6.6M for six months ended Sep 30, 2025 vs net income $57.8M in prior year period.","No revenue from operations; digital assets at fair value $132.3M (incl. restricted).","Total equity $132.3M, zero liabilities; unrealized loss $9.1M from digital asset remeasurement.","Financials filed as Exhibit 99.1 for reverse merger with Apimeds (APUS) previously reported.","Company holds crypto tokens ($NILA) and generates gains mainly from sale of digital assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110639,"accession_number":"0001213900-26-000464","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apimeds Pharmaceuticals removes director Erik Emerson via stockholder vote","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erik Emerson removed from board of directors effective December 30, 2025.","Removal effected by majority stockholder vote, with or without cause.","Remaining board: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127268,"accession_number":"0001213900-25-119894","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from Apimeds Pharmaceuticals board effective December 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Vin Menon and Amir A. Dossal resigned from the Board of Directors on December 5, 2025.","Resignations were not due to any disagreement with the company's operations, policies, or practices.","Dr. Vin Menon remains CEO of the company; no replacements for the vacant board seats announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127264,"accession_number":"0001213900-25-119893","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K/A","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Apimeds corrects Merger Agreement errors: Preferred Stock issuance rises to 90.9% of equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Corrected Merger Agreement removes Sections 2.05(b)/(d) (director appointment).","Common Stock Cap corrected from 29.9% to 0% of Acquiror Common Stock outstanding.","Preferred Stock issuable to Company stockholders corrected from 61% to 90.9% of fully diluted equity.","Corrected Certificate of Designation increases Series A Preferred designated shares from 7,263,865 to 7,477,017.","Amendment to Securities Purchase Agreement extends Initial Closing date and expands investor notification rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127267,"accession_number":"0001213900-25-117173","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","5.01","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Apimeds Pharmaceuticals US completes merger with MindWave Innovations, issues 90.9% equity to MindWave holders","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On Dec 1, 2025, Apimeds (APUS) merged with MindWave Innovations, with MindWave surviving as wholly owned subsidiary.","MindWave stockholders received 29.9% of Apimeds common stock and 61% convertible preferred (as-converted), totaling 90.9% of post-merger equity.","Apimeds entered a $120.9M convertible note financing with 8% OID, issuing senior convertible notes.","CEO Erik Emerson resigned, replaced by Dr. Vin Menon; two new directors appointed.","Apimeds will effect a 1-for-10 reverse stock split and increase equity plan shares to 2,096,679."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127266,"accession_number":"0001213900-25-112184","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Apimeds boosts CEO salary to $500K and adds 24-month severance with equity vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Erik Emerson's annual base salary increased to $500,000, effective Nov 13, 2025.","If terminated without cause, Emerson gets 24 months salary/benefits plus immediate vesting of all unvested equity.","On termination for cause or voluntary quit without good reason, unvested equity forfeited automatically.","Amendment modifies the original Sept 21, 2023 employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127265,"accession_number":"0001213900-25-099553","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Apimeds Pharmaceuticals amends bylaws to allow shareholder action by written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted First Amendment to Bylaws on October 15, 2025, effective immediately.","Amendment permits shareholders to take action by written consent without a meeting.","Change provides shareholders an additional mechanism to act outside of annual or special meetings.","No other changes to the bylaws were made; full amendment filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144057,"accession_number":"0001213900-25-064446","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Apimeds appoints Dr. Susan Kramer SVP Development, Brian Peters to lead ai² division","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Susan Kramer appointed SVP of Development; 30+ years experience including 18 at Genentech.","Brian Peters joins as Head of ai² division; previously Chief Strategy & Insights Officer at Heller Agency.","CEO Erik Emerson says strengthening operational leadership is a priority since IPO.","Dr. Kramer will oversee all product development; Peters will lead ai² platform strategy and launch.","Both appointments effective July 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162356,"accession_number":"0001213900-25-051567","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apimeds Pharmaceuticals appoints Erick J. Frim as CFO, replacing Mark Corrao","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erick J. Frim, 67, appointed CFO effective May 30, 2025, succeeding Mark Corrao.","Mr. Frim has over 40 years of financial management experience, most recently as interim CFO of Helio Corporation.","Compensation: $2,500 per month for first 8 hours, $250 per hour thereafter under a one-year consulting agreement.","No familial relationships or reportable related-party transactions with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162355,"accession_number":"0001213900-25-045643","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Apimeds extends maturity of three promissory notes to May 19, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended notes from Inscobee ($100k and $150k) and Apimeds Korea ($250k), total $500k principal.","Original maturity dates extended to May 19, 2026; interest remains 5% per annum.","May 2024 and August 2024 notes were due May 19, 2025; March 2025 note was due Dec 31, 2026 or upon NYSE listing.","Amendments executed on May 16, 2025, avoid imminent default on two notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162354,"accession_number":"0001213900-25-042122","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Apimeds Pharmaceuticals US completes $13.5M IPO; starts trading on NYSE American","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 3,375,000 shares at $4.00/share; gross proceeds $13.5M.","Proceeds to fund Phase III knee osteoarthritis trial, MS study, manufacturing, working capital.","Convertible notes of $772,545 converted into 297,133 shares at $2.60/share.","Underwriters granted 45-day option for 506,250 additional shares and warrants for 168,750 shares.","Trading began May 9, 2025 on NYSE American under symbol APUS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162353,"accession_number":"0001213900-25-032176","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Apimeds amends bylaws: reduces quorum, eliminates written consent, raises bar for director removal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum reduced from majority to 33 1/3% of outstanding shares.","Stockholders can no longer act by written consent; removal of directors is for cause only with 66 2/3% vote.","Advanced notice required for stockholder proposals and director nominations.","Board size fixed between 1 and 7 directors; Delaware forum selection clause added.","Amendments to bylaws require affirmative vote of 66 2/3% of voting power."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":20674912.161971834,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}